Protocol Ledger

NCT05395416 · Phase II/III · COMPLETED

Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C

Interventional Phase II/III clinical trial protocol NCT05395416 sponsored by Sunshine Lake Pharma Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-21 Enrollment: 514 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05395416
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)514 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05395416
Protocol FieldVerified Registry Value
NCT IdentifierNCT05395416
Consolidated Lead SponsorSunshine Lake Pharma Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment514 participants (ACTUAL)
Registered Start Date2021-06-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI